ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,732.93
      0.25%
      US Tech 100
      19,420.06
      0.51%
      Dow Jones
      42,208.22
      0.20%
      Brent Oil
      74.56
      1.12%
      Bitcoin
      64,259.86
      1.47%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Celyad Oncology SA (CYAD) Quote

      Celyad Oncology SA

      Celyad Oncology SA (CYAD)

      Celyad Oncology SA
      0.47
      0.00
      (0.00%)
      At close: September 24 4:00PM
      Delayed by 15 minutes
      0.47
      0.00
      ( 0.00% )
      After Hours: -
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      0.47
      Bid
      0.47
      Ask
      0.52
      Volume
      -
      0.00 Day's Range 0.00
      0.00 52 Week Range 0.00
      Market Cap
      19.472M
      Previous Close
      0.47
      Open
      -
      Last Trade
      Last Trade Time
      -
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      -
      Shares Outstanding
      41,429,000
      Dividend Yield
      -
      PE Ratio
      -1.32
      Earnings Per Share (EPS)
      -0.2
      Revenue
      102k
      Net Profit
      -8.45M

      About Celyad Oncology SA

      Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm h... Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.celyad.com
      Headquarters
      Mont-saint-guibert, Walloon Brabant, Bel
      Founded
      -

      Ask ADVFN Intelligence (AI)

      CYAD Latest News

      More News

      FeaturedCannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference

      10 hours ago

      FeaturedIntegrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC.

      10 hours ago

      Celyad Oncology annonce la nomination de Matt Kane au poste de CEO

      Regulatory News: Celyad Oncology SA (Euronext & Nasdaq : CYAD) (la « Société » ou « Celyad ») est heureuse d’annoncer la nomination de Matt Kane au poste de Directeur Général (Chief...

      September 16 2024
      Business Wire

      Celyad Oncology Reports First Half Year 2024 Financial Results and Recent Business Highlights

      The Company continues to bolster its intellectual property estate and to pursue options to monetize it The Company’s two main research and development platforms have delivered proof-of-concept...

      September 13 2024
      Business Wire

      Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights

      Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the “Company”), today announces its financial results for the fiscal year 2023 ended December 31, 2023, and provides a...

      April 04 2024
      Business Wire

      Celyad Oncology annonce son intention de mettre fin à ses obligations de déclaration à la SEC

      Regulatory News: Celyad Oncology SA (Euronext: CYAD) (« Celyad Oncology » ou la «Société») annonce que la Société déposera volontairement un Formulaire 15F auprès de la Securities and Exchange...

      February 08 2024
      Business Wire

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      January 17 2024
      Edgar (US Regulatory)

      Celyad Oncology fait le point sur les activités du quatrième trimestre 2023 et présente ses perspectives pour 2024

      Trois piliers principaux pour libérer le potentiel des plateformes technologiques propriétaires et de la propriété intellectuelle : Une plateforme technologique exclusive sans édition de génome...

      January 16 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      ELYMEliem Therapeutics Inc
      $ 10.23
      (55.95%)
      		1.19M
      MSGMMotorsport Games Inc
      $ 1.4801
      (34.55%)
      		2.6M
      XHGXChange TED Inc
      $ 1.52
      (26.67%)
      		2.9M
      FEAM5E Advanced Materials Inc
      $ 0.5045
      (23.53%)
      		2.04k
      GIFTRDE Inc
      $ 3.01
      (19.44%)
      		2k
      SFIXStitch Fix Inc
      $ 2.91
      (-22.40%)
      		1.19M
      ATXSAstria Therapeutics Inc
      $ 10.93
      (-12.56%)
      		50.22k
      TRNRInteractive Strength Inc
      $ 0.2319
      (-11.49%)
      		1.3M
      ULYUrgent ly Inc
      $ 0.713
      (-8.44%)
      		7.38k
      BNZIBanzai International Inc
      $ 7.55
      (-8.37%)
      		679.48k
      INTCIntel Corporation
      $ 22.8198
      (0.04%)
      		17.39M
      NVDANVIDIA Corporation
      $ 121.46
      (0.49%)
      		14.86M
      JGLOJP Morgan Global Select Equity ETF
      $ 62.28
      (0.00%)
      		13.85M
      ELABElevai Labs Inc
      $ 0.1185
      (15.05%)
      		11.08M
      LIPOLipella Pharmaceuticals Inc
      $ 0.5097
      (12.49%)
      		6.41M

      Discussion

      View Full Feed
      janice shell janice shell 1 minute ago
      Yes it is, in September. The SEC's fiscal year ends on the 30th.
      WAMUSHAMU WAMUSHAMU 2 minutes ago
      BAM! 💥
      COOP
      Penny2Dime Penny2Dime 2 minutes ago
      Nice!
      IFXY
      StockInfo11 StockInfo11 3 minutes ago
      W/ expectations of stimulus from China, copper is up, and as highlighted in a recent Libero Copper & Gold (LBC.v LBCMF) interview, the junior plans to capitalize on future copper price increases.
      https://youtu.be/9ZcmH9ZnMw0
      LBC's Mocoa project in Colombia has an estimated 4.6B lbs of
      LBCMF
      Kansasjack1 Kansasjack1 4 minutes ago
      Thanks for the Update!
      NBRI
      Eli's Gone Eli's Gone 4 minutes ago
      He's having a phenomenal year---that would be icing on the cake, along with the playoffs of course.
      price_and_volume price_and_volume 4 minutes ago
      This was promised 4 years ago, remember?
      You can add to that list NFL players that they will do deals with... I guess all the board-newbs won't recognize the re-hashed promises & pump from years ago.

      Warren Sapp, the GOAT, etc. Tell me you haven't forgotten?

      Nex
      AHRO
      vlispxpert vlispxpert 4 minutes ago
      CING radar
      CING
      goldslacker2023 goldslacker2023 5 minutes ago
      How many coal plants does it require to make an EV/batteries? Just asking 😀.
      GNCP
      TechandBio TechandBio 5 minutes ago
      IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
      https://www.prnewswire.com/news-releases/icecures-ice3-5-year-t
      ICCM
      janice shell janice shell 5 minutes ago
      Do you ever listen to the Podcast "Wait Wait Don't Tell me" on NPR? It's a game show of sorts where 3 panelist/comedians answer questions about recent news events.

      That sounds good. And the story about the 8-year-old is just great.
      RedSox04 RedSox04 5 minutes ago
      .001 break is close!
      CBDL
      Hoghead7 Hoghead7 5 minutes ago
      Yes, it was first announced in January, and I believe referenced in March 24 call and earnings report
      FCEL
      StockInfo11 StockInfo11 6 minutes ago
      At the 2024 Precious Metals Conference, Abitibi Metals' (AMQ.c AMQFF) CEO Jon Deluce highlighted their B26 Copper/Polymetallic and Beschefer Gold Projects.
      https://youtu.be/7CR7-2F03b4
      With strong financial backing, infrastructure, and upcoming catalysts AMQ aims to expand the resourc
      AMQFF
      rollingrock rollingrock 6 minutes ago
      I bought a 2009 Nissan Versa a year
      and a half ago to be my beater around town. High mileage but I knew the owner and it was in good shape. A 6 speed manual
      and fun to drive, easy to park, no bells and whistles. On Good Friday I got T-boned and the insurance company scrapped the car. I
      J0L J0L 6 minutes ago
      It’s a bullish sign they are here. Be welcoming lol…
      ICTY
      goldslacker2023 goldslacker2023 6 minutes ago
      Wowzers!
      GNCP
      ysung ysung 6 minutes ago
      Excellent !!
      NBRI
      Teetrixxx Teetrixxx 7 minutes ago
      Since you are always spot on regarding GS tickers. I am very interested to hear your opinion about the future of HMBL’s PPS if the market turns around and becomes bullish. Where would you see HMBL going if a bull market comes one day?
      HMBL
      Looking4BIGcash Looking4BIGcash 8 minutes ago
      Hey Owl. I'm good. Had fun at the Olympics in Paris... watched Beach Volleyball from the Eiffel Tower beside official Olympic photographers.
      I don't see a ton happening here until the Spring but that should be good to accumulate a little more on the cheap (speaking about myself).
      It
      WDDD
      Giovanni Giovanni 9 minutes ago
      None of these companies has ever reordered their 1 carton trial run.

      LOL

      History is meaningless....
      XXII
      JJones65 JJones65 9 minutes ago
      If you read the terms of the deal, IMO, it's just another desperation cash grab before they reverse split or something worse.
      Investor082 Investor082 9 minutes ago
      How many preferred C do they have remaining?
      NWBO
      ChartMasterpieces ChartMasterpieces 9 minutes ago
      You could say 15 is a major resistance. If broken, 25
      Should follow imo.
      SINC

      Your Recent History

      NASDAQ
      CYAD
      Celyad Oncology
      Delayed Upgrade Clock